Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors

Cancer Discovery

Volumn 3, Issue 7, 2013, Pages 742-750

  Morris, Erick J ^a   Jha, Sharda ^a   Restaino, Clifford R ^a   Dayananth, Priya ^a   Zhu, Hugh ^a   Cooper, Alan ^a   Carr, Donna ^a   Deng, Yongi ^a   Jin, Weihong ^a   Black, Stuart ^a   Long, Brian ^a   Liu, Jenny ^a   DiNunzio, Edward ^a   Windsor, William ^a   Zhang, Rumin ^a   Zhao, Shuxia ^a   Angagaw, Minilik H ^a   Pinheiro, Elaine M ^a   Desai, Jagdish ^a   Xiao, Li ^a   Shipps, Gerald ^a   Hruza, Alan ^a   Wang, James ^a   Kelly, Joe ^a   Paliwal, Sunil ^a   Gao, Xiaolei ^a   Babu, Boga Sobhana ^a   Zhu, Liang ^a   Daublain, Pierre ^a   Zhang, Ling ^b   Lutterbach, Bart A ^a   Pelletier, Marc R ^a   Philippar, Ulrike ^a   Siliphaivanh, Phieng ^a   Witter, David ^a   Kirschmeier, Paul ^a,c   Robert Bishop, W ^a   Hicklin, Daniel ^a   Gary Gillil, D ^a   Jayaraman, Lata ^a   Zawel, Leigh ^a   Fawell, Stephen ^a,d   Samatar, Ahmed A ^a   more..

^a MERCK RESEARCH LABORATORIES   (United States)

^b Department of Clinical Research Oncology ^*  (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; SCH 772984; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL CYCLE; CELL PROLIFERATION; CELL VIABILITY; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA SEQUENCE; DRUG DESIGN; DRUG STRUCTURE; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN CELL; MELANOMA; MOUSE; NONHUMAN; REAL TIME POLYMERASE CHAIN REACTION; TUMOR GROWTH; TUMOR REGRESSION; TUMOR VOLUME; WESTERN BLOTTING;

CELL LINE, TUMOR; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; MAP KINASE KINASE KINASES; MUTATION; NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; SIGNAL TRANSDUCTION;

EID: 84880254869     PISSN: 21598274     EISSN: 21598290     Source Type: Journal    
DOI: 10.1158/2159-8290.CD-13-0070     Document Type: Article

References (24)

1. Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 2012; 367: 1694-703.
2. Flaherty KT, Hodi FS, Fisher DE. From genes to drugs: targeted strategies for melanoma. Nat Rev Cancer 2012; 12: 349-61.
3. Little AS, Smith PD, Cook SJ. Mechanisms of acquired resistance to ERK1/2 pathway inhibitors. Oncogene 2013; 32: 1207-15.
4. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364: 2507-16.
5. Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, Milhem M, et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 2012; 367: 107-14.
6. Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, openlabel, phase 3 randomised controlled trial. Lancet 2012; 380: 358-65.
7. Flaherty KT, Yasothan U, Kirkpatrick P. Vemurafenib. Nat Rev 2011; 10: 811-2.
8. Lemech C, Infante J, Arkenau HT. The potential for BRAF V600 inhibitors in advanced cutaneous melanoma: rationale and latest evidence. Ther Adv Med Oncol 2012; 4: 61-73.
9. Greger JG, Eastman SD, Zhang V, Bleam MR, Hughes AM, Smitheman KN, et al. Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations. Mol Cancer Ther 2012; 11: 909-20.
10. Shi H, Moriceau G, Kong X, Lee MK, Lee H, Koya RC, et al. Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance. Nat Commun 2012; 3: 724.
11. Annis DA, Cheng CC, Chuang CC, McCarter JD, Nash HM, Nazef N, et al. Inhibitors of the lipid phosphatase SHIP2 discovered by highthroughput affinity selection-mass spectrometry screening of combinatorial libraries. Comb Chem High Throughput Screen 2009; 12: 760-71.
12. Aronov AM, Tang Q, Martinez-Botella G, Bemis GW, Cao J, Chen G, et al. Structure-guided design of potent and selective pyrimidylpyrrole inhibitors of extracellular signal-regulated kinase (ERK) using conformational control. J Med Chem 2009; 52: 6362-8.
13. Hatzivassiliou G, Liu B, O'Brien C, Spoerke JM, Hoeflich KP, Haverty PM, et al. ERK inhibition overcomes acquired resistance to MEK inhibitors. Mol Cancer Ther 2012; 11: 1143-54.
14. Pratilas CA, Solit DB. Targeting the mitogen-activated protein kinase pathway: physiological feedback and drug response. Clin Cancer Res 2010; 16: 3329-34.
15. Dougherty MK, Muller J, Ritt DA, Zhou M, Zhou XZ, Copeland TD, et al. Regulation of Raf-1 by direct feedback phosphorylation. Mol Cell 2005; 17: 215-24.
16. Alcala AM, Flaherty KT. BRAF inhibitors for the treatment of metastatic melanoma: clinical trials and mechanisms of resistance. Clin Cancer Res 2012; 18: 33-9.
17. Emery CM, Vijayendran KG, Zipser MC, Sawyer AM, Niu L, Kim JJ, et al. MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci U S A 2009; 106: 20411-6.
18. Poulikakos PI, Persaud Y, Janakiraman M, Kong X, Ng C, Moriceau G, et al. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature 2011; 480: 387-90.
19. Corcoran RB, Dias-Santagata D, Bergethon K, Iafrate AJ, Settleman J, Engelman JA. BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation. Sci Signal 2010; 3: ra84.
20. Wagle N, Emery C, Berger MF, Davis MJ, Sawyer A, Pochanard P, et al. Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol 2011; 29: 3085-96.
21. Wang H, Daouti S, Li WH, Wen Y, Rizzo C, Higgins B, et al. Identification of the MEK1(F129L) activating mutation as a potential mechanism of acquired resistance to MEK inhibition in human cancers carrying the B-RafV600E mutation. Cancer Res 2011; 71: 5535-45.
22. Corcoran RB, Ebi H, Turke AB, Coffee EM, Nishino M, Cogdill AP, et al. EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov 2012; 2: 227-35.
23. Kim KB, Kefford R, Pavlick AC, Infante JR, Ribas A, Sosman JA, et al. Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. J Clin Oncol 2013; 31: 482-9.
24. Shi H, Kong X, Ribas A, Lo RS. Combinatorial treatments that overcome PDGFRbeta-driven resistance of melanoma cells to V600EBRAF inhibition. Cancer Res 2011; 71: 5067-74.